A review of transdermal hormonal contraception: Focus on the ethinylestradiol/norelgestromin contraceptive patch

Treatments in Endocrinology

Volumn 5, Issue 6, 2006, Pages 359-365

  Graziottin, Alessandra ^a,b  

^a Center of Gynecology and Medical Sexology   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DIENOGEST; ETHINYLESTRADIOL PLUS NORELGESTROMIN; LEVONORGESTREL; NANDROLONE; NORELGESTROMIN; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROGESTERONE RECEPTOR; CONTRACEPTIVE AGENT; ETHINYLESTRADIOL;

ABDOMINAL PAIN; ACNE; APPLICATION SITE REACTION; BREAST DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; GASTROINTESTINAL ABSORPTION; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; LIVER METABOLISM; MASTALGIA; NAUSEA; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; REVIEW; TRANSDERMAL PATCH; VAGINA RING; VENOUS THROMBOEMBOLISM; CONTRACEPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; HUMANS; NANDROLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSDERMAL PATCH;

EID: 33751206814     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605060-00004     Document Type: Review

References (36)

1. Rosenberg MJ, Waugh MS, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med 1995; 40 (5): 355-60
2. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51 (5): 283-8
3. Kubba A, Guillebaud J, Anderson RA, et al. Contraception. Lancet 2000; 356 (9245): 1913-9
4. Sitruk-Ware R. Vaginal delivery of contraceptives. Expert Opin Drug Deliv 2005; 2 (4): 729-36
5. Johansson ED, Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am J Obstet Gynecol 2004; 190 (4 Suppl.): S54-9
6. Smallwood GH, Meador ML, Lenihan JP, et al. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001; 98 (5 Pt 1): 799-805
7. Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285 (18): 2347-54
8. Hedon B, Helmerhorst FM, Cronje HS. Comparison of efficacy, cycle control, compliance, and safety in users of a contraceptive patch vs an oral contraceptive [abstract]. Int J Gynaecol Obstet 2000; 70 Suppl. 1: 78
9. Sibai BM, Odlind V, Meador ML, et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril 2002; 77 (2 Suppl. 2): S19-26
10. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004; 3 (2): 115-24
11. Janssen-Cilag International N.V. Evra transdermal patch: summary of product characteristics. Beerse: Janssen-Cilag International N.V., 2002
12. Burkman RT. Pharmacologic characteristics of progestins used for contraception and hormone replacement therapy, including new transdermal technologies. Am J Manag Care 2001; 7 (18 Suppl.): S571-4
13. Stanczyk FZ. All progestins are not created equal. Steroids 2003; 68 (10-13): 879-90
14. Henzl MR. Norgestimate: from the laboratory to three clinical indications. J Reprod Med 2001; 46 (7): 647-61
15. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003; 46 Suppl. 1: S7-16
16. Abrams LS, Skee D, Natarajan J, et al. Pharmacokinetic overview of Ortho Evra/Evra. Fertil Steril 2002; 77 (2 Suppl. 2): S3-12
17. Phillips A, Hahn DW, McGuire JL. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity. Am J Obstet Gynecol 1992; 167 (4 Pt 2): 1191-6
18. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am J Obstet Gynecol 2005; 192 (6): 2055-9
19. Rabe T, Kowald A, Ortmann J, et al. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000; 14 (4): 223-30
20. Sator PG, Schmidt JB, Honigsmann H. Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris: a pilot study. Dermatology 2003; 206 (3): 241-8
21. Pasqualini JR. Differential effects of progestins on breast tissue enzymes. Maturitas 2003; 46 Suppl. 1: S45-54
22. Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77 (2 Suppl. 2): S13-8
23. Burkman RT. The transdermal contraceptive system. Am J Obstet Gynecol 2004; 190 (4 Suppl.): S49-53
24. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999; 31 (2): 64-72, 93
25. Fu H, Darroch JE, Haas T, et al. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999; 31 (2): 56-63
26. Emans SJ, Grace E, Woods ER, et al. Adolescents' compliance with the use of oral contraceptives. JAMA 1987; 257 (24): 3377-81
27. Archer DF, Cullins V, Creasy GW, et al. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception 2004; 69 (3): 189-95
28. Archer DF, Bigrigg A, Smallwood GH, et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril 2002; 77 (2 Suppl. 2): S27-31
29. Rubinstein ML, Halpern-Felsher BL, Irwin Jr CE. An evaluation of the use of the transdermal contraceptive patch in adolescents. J Adolesc Health 2004; 34 (5): 395-401
30. Logsdon S, Richards J, Omar HA. Long-term evaluation of the use of the transdermal contraceptive patch in adolescents. ScientificWorldJournal 2004; 4: 512-6
31. Weisberg F, Bouchard C, Moreau M, et al. Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study. J Obstet Gynaecol Can 2005; 27 (4): 350-9
32. Lippi G, Manzato F, Brocco G, et al. Prothrombotic effects and clinical implications of third-generation oral contraceptives use. Blood Coagul Fibrinolysis 2002; 13 (1): 69-72
33. Lippman JS, Shangold GA. A review of post-marketing safety and surveillance data for oral contraceptives containing norgestimate and ethinyl estradiol. Int J Fertil Womens Med 1997; 42 (4): 230-9
34. Jick SS, Kaye JA, Russman S, et al. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2006; 73 (3): 223-8
35. Council for International Organizations of Medical Sciences (CIOMS). Guidelines for preparing core clinical-safety information of drugs. 2nd ed. Geneva: CIOMS, 1998
36. Sonnenberg FA, Burkman RT, Speroff L, et al. Cost-effectiveness and contraceptive effectiveness of the transdermal contraceptive patch. Am J Obstet Gynecol 2005; 192 (1): 1-9